Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Empagliflozin improves nighttime glycemia in type 1 diabetes
Última actualización 18 de agosto de 2026
Key finding
HbA1c improved from 8.03±0.91 to 7.62±0.15% over the 8-week baseline to end-of-treatment periods (p<0.0001).
Empagliflozin added to insulin therapy in adults with type 1 diabetes.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
Empagliflozin added to insulin therapy in adults with type 1 diabetes.
Clinical relevance
This study evaluated Empagliflozin added to insulin therapy in adults with type 1 diabetes.
Keep in mind
Limitations were not clearly described in the extracted text.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Bruce AP, David ZIC, Nima S, et al. Empagliflozin Improves Nighttime Glycemia in Adults with Type 1 Diabetes. PLOS ONE. 2015;10(11):e0141085. doi:10.1371/journal.pone.0141085
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Empagliflozin and Glucose variability, HbA1c, Time to glycemic target.
This study contributes evidence to
Primary intervention
Empagliflozin
Primary outcomes
- Glucose variability
- HbA1c
- Time to glycemic target
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
3
Evidence pairs
3
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
3
Related topics
3
Evidence pairs
738
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 3 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
SGLT2 Inhibitors and HbA1c
Evidencia relacionada
Relación de evidencia
SGLT2 Inhibitors and CGM Time in Range
Guardar evidencia
Relación de evidencia
SGLT2 Inhibitors and Glucose Variability
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 81
- Positive
- ConsistencyScore™
- 88
- consistent
Estudios de apoyo: Basado en 8 estudios
Add to Evidence TrackerTime to glycemic target
Empagliflozin → Time to glycemic target
Empagliflozin → Time to glycemic target
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on SGLT2 Inhibitors and HbA1c, SGLT2 Inhibitors and Glucose Variability.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
SGLT2 Inhibitors → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 81
- Positive
- ConsistencyScore™
- 88
- consistent
Estudios de apoyo: Basado en 8 estudios
View evidenceMedications
SGLT2 Inhibitors → Glucose Variability
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
HbA1c Evidence Hub
All studies measuring HbA1c
8 studies
outcome_hubMeasures HbA1c as a key outcome.
SGLT2 Inhibitors Evidence Hub
All studies on SGLT2 Inhibitors
8 studies
intervention_hubContributes to SGLT2 Inhibitors evidence base.
Glucose Variability Evidence Hub
All studies measuring Glucose Variability
1 studies
outcome_hubMeasures Glucose Variability as a key outcome.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Empagliflozin and HbA1c
Intervention: EmpagliflozinOutcome: HbA1c
8 results
All studies on Empagliflozin and Glucose variability
Intervention: EmpagliflozinOutcome: Glucose variability
1 results
All studies on Empagliflozin
Intervention: Empagliflozin
8 results
All studies measuring HbA1c
Outcome: HbA1c
8 results
All studies measuring Glucose variability
Outcome: Glucose variability
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does SGLT2 Inhibitors improve HbA1c?
Strong Evidence
SGLT2 Inhibitors may improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.4 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 17 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does SGLT2 Inhibitors improve cgm time in range?
Strong Evidence
SGLT2 Inhibitors may improve CGM Time in Range.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Time to glycemic target
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 3 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does SGLT2 Inhibitors improve glucose variability?
Emerging Evidence
Current evidence does not show a clear benefit of SGLT2 Inhibitors for Glucose Variability.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Glucose variability
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Combination therapy improves liver health in type 2 diabetesEmpagliflozin improves heart function in type 2 diabetes patientsEmpagliflozin improves glycemic control in type 2 diabetes patientsEmpagliflozin may reduce kidney disease biomarkers but shows mixed effects on albumin in early diabetesEmpagliflozin reduces liver fat in diabetes patients
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.